COVID-19 Vaccine Cleared to Start Phase 2 Clinical Trial
An mRNA-based vaccine has completed a phase 1 clinical trial on 8 healthy adults. The vaccine is on track to begin a larger phase 2 study on 600 volunteers, and if shown to be effective, would move on to the final phases of testing. If the vaccine is proven safe and effective, it could be made available by early next year. The manufacturer, Moderna, says it is “doing our best to make it as many millions as possible.” Health assert that it is important for multiple vaccines to be developed because demand will greatly exceed the production capabilities of any single company.
Full Story: New York Times